Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jeff Goater
AddedMar 31, 2024
UpdatedMay 31, 2026
Jeff Goater

Jeff Goater

Board Member, Atavistik Bio

LinkedIn

Jeff Goater's Career

Atavistik Bio
Atavistik Bio

Cambridge, MA, US

Board Member· Board
Judo Bio
Judo Bio

Cambridge, MA, US

Board Member· Board
Ribon Therapeutics
Ribon Therapeutics

Cambridge, MA, US

Board Member· Board
Kallyope
Kallyope

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jeff Goater's Career

Atavistik Bio
Atavistik Bio
Private Equity$100M362021Cambridge, MA, US
Board Member· Board

Leadership at Atavistik Bio

Jared RutterJared RutterCo-Founder
Thilo SchroederThilo SchroederBoard Member
Ralph J DeBerardinisRalph J DeBerardinisCo-Founder
Judo Bio
Judo Bio
Seed$25M5Cambridge, MA, US
Board Member· Board
Ribon Therapeutics
Ribon Therapeutics
Series B$259M572015Cambridge, MA, US
Board Member· Board

Leadership at Ribon Therapeutics

Jon RootJon RootBoard Member
Peter SvennilsonPeter SvennilsonBoard Member
Jodie MorrisonJodie MorrisonBoard Member
Paul ChangPaul ChangCo-Founder
Jim AudiaJim AudiaBoard Member
Tim MitchisonTim MitchisonCo-Founder

Similar to Ribon Therapeutics

RibonovaRibonovaWynnewood, PA, USPharmaceuticalsest. 2011RibonovaWynnewood, PA, US · est. 2011

US-based Ribonova Inc, founded in 2011, specializes in manufacturing pharmaceuticals for human and veterinary use.

Angel · $25k5
RibometrixRibometrixGreenville, NC, USDrug Discoveryest. 2014RibometrixGreenville, NC, US · est. 2014

Ribometrix, a US-based biotech firm, leverages 3D RNA analysis for novel drug discovery.

Series A · $45.3M29
ENB TherapeuticsENB TherapeuticsNew York City, NY, USCancer Therapeuticsest. 2015ENB TherapeuticsNew York City, NY, US · est. 2015

ENB Therapeutics, Inc.: A US-based biopharmaceutical firm developing novel inhibitors to treat cancers.

Series A · $8.2M8
Redona TherapeuticsRedona TherapeuticsWatertown, MA, USCancer Treatmentest. 2016Redona TherapeuticsWatertown, MA, US · est. 2016

Redona Therapeutics: Advancing small molecule therapies for cancer via ncRNA modulation.

Series A · $66.8M24
Kallyope
Kallyope
Series A$487.2M1082015New York City, NY, US
Board Member· Board

Leadership at Kallyope

Charles ZukerCharles ZukerCo-Founder
Richard AxelRichard AxelCo-Founder
Peter HechtPeter HechtBoard Member
Bill RieflinBill RieflinBoard Member
Jay GaleotaJay GaleotaBoard Member
Amy SchulmanAmy SchulmanBoard Member

Similar to Kallyope

Bloom ScienceBloom ScienceSan Diego, CA, USDrugs, Therapeuticsest. 2018Bloom ScienceSan Diego, CA, US · est. 2018

Bloom Science: A biotech firm innovating gut-brain axis targeted drugs for neurology, immunology, and oncology.

Series A · $12M17
KalypsysKalypsysSan Diego, CA, USDrug Development, Drug Discoveryest. 2001KalypsysSan Diego, CA, US · est. 2001

Kalypsys: Automated, integrated drug discovery and development across multiple therapeutic areas.

Series C · $171M175
EnterinEnterinPhiladelphia, PA, USBiomedical Products, Therapiesest. 2016EnterinPhiladelphia, PA, US · est. 2016

Enterin, Inc.: Global provider of innovative biomedical products and therapies for neurodegenerative diseases.

Series A · $81.6M26
Axial TherapeuticsAxial TherapeuticsWoburn, MA, USTherapeuticsest. 2016Axial TherapeuticsWoburn, MA, US · est. 2016

Axial Biotherapeutics develops gut-restricted small molecules for treating central nervous system disorders.

Series C · $110.9M29

Jeff Goater's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Jeff Goater

John JoseyJohn JoseyBoard Member · Circle PharmaSteven WattSteven WattCEO · Atterx BioTherapeuticsJim CorbettJim CorbettBoard Member · AVITA MedicalJeff JonasJeff JonasBoard Member · Generation Bio